The Living Guidelines: STEMI Antiplatelet Therapy Polling Results for CLASS IIa Guidelines

1- In patients <75 years of age who receive fibrinolytic therapy or who do not receive reperfusion therapy, it is reasonable to administer an oral loading dose of clopidogrel 300 mg. (Class II a, Level of Evidence: C) (No data are available to guide decision making regarding an oral loading dose in patients 75 years of age or older.)

 Antiplatelet Therapy CLASS IIa Recommendation 1 should be: CLASS I CLASS IIa CLASS IIb CLASS III

2- Long-term maintenance therapy (e.g., 1 year) with clopidogrel (75 mg / day orally) is reasonable in STEMI patients regardless of whether they undergo reperfusion with fibrinolytic therapy or do not receive reperfusion therapy. Class II a (Level of Evidence: C)

 Antiplatelet Therapy CLASS IIa Recommendation 2 should be: CLASS I CLASS IIa CLASS IIb CLASS III